Key Points
- Bpifrance Epic sold 1,292,103 DBV shares on Dec. 18 at an average $4.19 (and 2,076,990 shares on Dec. 17 at $4.85), a combined ≈3.37M‑share sale that cut its stake by 15.03% and could exert downward pressure on the stock.
- Offsetting the selling, DBV has fresh bullish momentum from a reported Phase‑III win in peanut allergy and multiple analyst upgrades (consensus rating: Moderate Buy) with substantially higher price targets.
- Despite positive catalysts, the company remains loss‑making (consensus EPS ~($7.05)), so near‑term profitability and cash‑runway risks remain key investor considerations.
DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) major shareholder Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the transaction, the insider owned 7,303,369 shares of the company's stock, valued at $30,601,116.11. The trade was a 15.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Bpifrance Epic also recently made the following trade(s):
- On Wednesday, December 17th, Bpifrance Epic sold 2,076,990 shares of DBV Technologies stock. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50.
DBV Technologies Price Performance
Shares of NASDAQ:DBVT opened at $22.76 on Friday. The company has a market capitalization of $914.04 million, a PE ratio of -4.40 and a beta of -1.10. The business has a fifty day moving average price of $15.38 and a 200-day moving average price of $11.83. DBV Technologies S.A. has a 1-year low of $2.92 and a 1-year high of $26.18.
Key Headlines Impacting DBV Technologies
Here are the key news stories impacting DBV Technologies this week:
- Positive Sentiment: Phase‑III win in peanut allergy improves commercial/clinical outlook — a Bioworld report says DBV’s VIT® program delivered a positive Phase III result, a material de‑risking event for a lead program that can drive future revenue and re‑rating. Vitesse finesse pays off: DBV wins in peanut allergy phase III
- Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts, signaling stronger long‑term profitability expectations (FY2027–FY2029 upgrades). That upward revision likely helped investor sentiment and price momentum. HC Wainwright Expects Stronger Earnings for DBV Technologies
- Positive Sentiment: Additional bullish analyst notes and coverage changes — the stock was reported to hit a new 1‑year high after analyst upgrades, and coverage consensus sits around a “Moderate Buy,” with at least one firm (Citizens JMP) forecasting strong price appreciation. Those actions typically boost retail/institutional interest. DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
- Neutral Sentiment: Market consensus EPS remains deeply negative for the current year (consensus ~($7.05) EPS), so while upgrades are meaningful, the company is still transitioning from loss‑making to profitable — investors should watch upcoming milestones and cash runway closely.
- Negative Sentiment: Major shareholder Bpifrance Epic sold large blocks of stock on Dec 17–18 (combined ~3.37M shares sold across two days, materially reducing its stake). Large insider/major‑holder selling can pressure the stock and signal liquidity‑driven exits even when fundamentals improve. SEC filing: Bpifrance Epic Insider Sales SEC Filing
- Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (worse near‑term profitability view), a reminder that boutique analysts still see near‑term execution and cash burn risk — this can cap upside until revenue/profitability is proven.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research report on Thursday. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research note on Friday, November 28th. Citigroup restated an "outperform" rating on shares of DBV Technologies in a research note on Wednesday. Citizens Jmp upped their price target on DBV Technologies from $21.00 to $45.00 and gave the company a "market outperform" rating in a report on Wednesday. Finally, Cantor Fitzgerald set a $48.00 price objective on DBV Technologies in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.38.
Check Out Our Latest Stock Report on DBVT
Hedge Funds Weigh In On DBV Technologies
Several institutional investors have recently made changes to their positions in the business. New York State Common Retirement Fund bought a new stake in DBV Technologies during the third quarter valued at approximately $34,000. Two Sigma Investments LP bought a new stake in shares of DBV Technologies during the 3rd quarter valued at $167,000. Citadel Advisors LLC purchased a new stake in shares of DBV Technologies in the 3rd quarter worth $220,000. DLD Asset Management LP bought a new position in DBV Technologies in the 3rd quarter worth $250,000. Finally, Nan Fung Trinity HK Ltd. bought a new stake in DBV Technologies during the second quarter valued at about $340,000. Institutional investors own 71.74% of the company's stock.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.
The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
